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ON STABILITY OF A COMBINED GLEEVEC AND
IMMUNE MODEL IN CHRONIC LEUKEMIA:
EXPLOITING DELAY SYSTEM STRUCTURE
Silviu-Iulian Niculescu 1 Peter S. Kim 2 Peter P. Lee 3
Doron Levy 4
Abstract: This paper focuses on the stability analysis of a delay-differential system
encountered in modeling immune dynamics during Gleevec treatment for chronic myel-
ogenous leukemia. A simple algorithm is proposed for the analysis of delay effects on
the stability. The analysis shows that the model yields two fixed points, one stable and
one unstable. The stable fixed point corresponds to some equilibrium solution in which
the leukemia population is kept below the cytogenetic remission level. This result implies
that, during Gleevec treatment, the resulting anti-leukemia immune response can serve to
control the leukemia population. However, the rate of approach to the stable fixed point
is very slow, indicating that the immune response is largely ineffective at driving the
leukemia population towards the stable fixed point. Finally, a few remarks are made about
possible treatment strategies that can be used to accelerate the approach of the leukemia
and immune populations towards this stable equilibrium. Copyright c©2007 IFAC.
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1. INTRODUCTION, AND PROBLEM
FORMULATION
The stability analysis of delay differential equations
(DDEs) that model biological phenomena is of recur-
ring interest Kuang [1993], Muray [1993]. In particu-
lar, we are concerned with delay models involving the
immune response to chronic myelogenous leukemia
(CML). A simple DDE model for the immune re-
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sponse in CML is due to Neiman [2002]. This work
tried to explain the transition of leukemia from the
stable chronic phase to the erratic accelerated and
acute phases. A more recent work is of Moore and Li
[2004]. They devised a CML model composed of a
system of ODEs (without delays). The main goal was
to examine which parameters are the most important
in influence the success of cancer remission. Chen
et al [2007] formulate a system of DDEs to model
the dynamics of anti-leukemia T cells during Gleevec
treatment for CML. The model is derived by taking
the original Gleevec model of Michor et al [2005] and
adding a DDE to simulate the population dynamics
of anti-leukemia T cells. In the paper, we analyze the
DDE system from the Chen model.
Gleevec works by inhibiting the abltyrosine kinase
that drives CML Angestreich et al [2004] and has
become the first-line therapy for CML. With Gleevec,
nearly all patients achieve hematologic remission
Cortes et al [2005], Lee [2000]; however, patients
relapse upon Gleevec discontinuation Cortes et al
[2005]. Thus, strategies to enhance Gleevec’s efficacy
are needed. Combining Gleevec with immunotherapy
represents a promising strategy; however, the role of
the immune response remains unclear. In vitro, ima-
tinib renders leukemic cells immunogenic Mohty et
al [2004], Sato [2003]. More specifically, low fre-
quency (generally < 1%) CD8+ T cell responses to
4 leukemia-associated antigens (LAAs) were detected
in CML patients after therapy with Gleevec Gannage
et al [2005]. Chen et al [2007] conduct further exper-
iments to follow the time evolution of anti-leukemia
T cells during Gleevec treatment. With this data, they
formulate a DDE model based on the observed dy-
namics. The time delay in Chen et al [2007] corre-
sponds to the duration of T cell proliferation cycles.
Their mathematical model is formulated as a nonlinear
delay-differential system. Its linearization around the
equilibrium point of interest writes as follows:
x˙(t) = A0x(t) + bcTx(t− nτ), (1)
under appropriate initial conditions defined on the in-
terval [−nτ, 0], where τ represents the delay, and n
some averaging factor. In our case study (A0 ∈ R5×5,
b, c ∈ R5×1), the system (1) has the following “limit”
properties: (a) the system free of delays is asymptoti-
cally stable, that is σ(A0+ bcT ) ∈ C−, and (b) the re-
duced system including only the “instantaneous” part
is hyperbolic, that is the matrix A0 has no eigenvalues
on the imaginary axis, i.e. σ(A) ∩ jR = ø.
The problem considered in the sequel can be resumed
as follows: under the assumptions above, find simple
conditions for characterizing the delay effects on sta-
bility of the linearized Gleevec model.
2. PRELIMINARY RESULTS
Consider now the following meromorphic function
q : C× R+ 7→ C:
q(λ, h) = 1− a(λ)e−λh, (2)
associated to the system (1), where a denotes the
transfer a(λ) = cT (λIn − A0)−1b, and h = nτ .
By exploiting the particular structure of the delayed
matrix bcT of rank one, we have the following results
(see, the full version of the paper for the complete
proofs Niculescu et al [2007]):
Proposition 1. Consider the system (1). Assume that
A0 has no eigenvalues on the imaginary axis, and that
1 − a(0) 6= 0, where a(λ) = cT (λIn − A)−1b.
Define now the function f : R − {0} 7→ R, f(ω) =
1− | a(jω) |. Under these conditions the following
statements are true:
(i) Suppose that f(ω) = 0 has no strictly positive roots
ω > 0. Then if (1) is stable at h = 0, it remains stable
for all h ≥ 0, whereas if it is unstable at h = 0 it
remains unstable for all h ≥ 0, and there does not
exist any root crossing the imaginary axis when the
delay h is increased in R+.
(ii) Suppose that f(ω) = 0 has at least one positive
root, and that each root is simple. As h increases,
stability switches may occur. There exists a positive
number h∗, such that the system (1) is unstable for all
h > h∗. As h varies from 0 to h∗, at most a finite
number of stability switches may occur. Furthermore,
if for ω = ω0 one pair of roots lies on the imaginary
axis, the roots will cross the imaginary axis from left
to right (or from right to left) if and only if:
<
[
a(jω0)
jω0cT b
]
< 0 (> 0). (3)
Next, the characterization of the stability with respect
to the delay is reduced to: (i) the computation of the
stability crossing set Ω, that is the set of all ω0 ∈ R+
for which q(λ, h) = 0 has at least one characteristic
root on jR (λ = jω0). It is important to point out that
card(Ω) is finite; (ii) the computation of the crossing
direction for all ω ∈ Ω. In conclusion, we have the
following computational procedure:
(1) Identification of the crossing set Ω - by a frequency
sweeping test: | a(jω) | against ω. A frequency ω0 ∈
Ω if and only if | a(jω0) |= 1. The condition 1 −
a(0) 6= 0 in Proposition 1 says that 0 6∈ Ω (i.e. no
invariant root at origin).
(2) Computation of the crossing delay set T : For each
crossing frequency, the corresponding critical delay
values are computed by using: ejω0h = a(jω0), that
is 5 T (ω0) =:{
h ∈ R+ : h = 1
ω0
[−jLog(a(jω0)) + 2pi`]
}
.
Finally, T is defined by:
T =
⋃
ω∈Ω
T (ω).
(3) Computation of the individual crossing directions:
In our case, the crossing direction characterization
reduces to the analysis of the sign of <(−ja(jω0))
for all ω0 ∈ Ω since cT b = 2nqT p¯1 > 0.
3. MAIN RESULTS
Mathematical model. Chen et al [2007] formulated a
DDE model combining the Gleevec dynamics of Mi-
chor et al [2005] with a T cell response. For this anal-
ysis, we exclude the possibility of Gleevec-resistance
mutations and analyze the following DDE system:
y˙0 = [ry − d0]y0 − qCp(C, T )y0, (4)
y˙1 = ayy0 − d1y1 − qCp(C, T )y1, (5)
y˙2 = byy1 − d2y2 − qCp(C, T )y2, (6)
y˙3 = cyy2 − d3y3 − qCp(C, T )y3, (7)
T˙ = sT − dTT − p(C, T )C + 2np(Cnτ , Tnτ )qTCnτ ,
(8)
5 Here, “Log” denotes the principal value of the logarithm. Conse-
quently for |z| = 1, Log(z) = j arg(z) with arg(z) ∈ (−pi, pi].
where
p(C, T ) = p0e−cnCkT, C =
3∑
i=0
yi,
Cnτ = C(t− nτ), Tnτ = T (t− nτ).
The variables y0, y1, y2, and y3 denote the concen-
trations of leukemia hematopoietic stem cells (SC),
progenitors (PC), differentiated cells (DC), and ter-
minally differentiated cells (TC) without resistance
mutations to Gleevec. The rate constants a, b, and c
are given with indices corresponding to non-resistant
and resistant leukemia populations. The death rates
of the four cell categories are given by d0, d1, d2,
and d3 respectively. The variable C denotes the total
concentration of all leukemia cells. The variable T
denotes the concentration of anti-leukemia T cells.
The final terms in each of the equations in (4) are
of the form qCp0e−cnCkTyi. We assume the law of
mass action, stating that two cell populations interact
at a rate proportional to the product of their concen-
trations. Hence, the component kTyi (or kTzi) is the
rate of interaction between T cells and the leukemia
subpopulation yi where k is the kinetic coefficient.
The coefficient p0 is the probability that a T cell en-
gages the cancer cell upon interaction, and qC is the
probability that the cancer cell dies from the T cell
response. Furthermore, leukemia cells suppress anti-
leukemia immune responses, and while the precise
mechanism is unknown, we assume that the level of
down-regulation depends on the current cancer popu-
lation. In particular, we model that the probability that
a T cell engages a cancer cell decays exponentially as
a function of the cancer concentration, i.e., the proba-
bility of a productive T cell interaction with a cancer
cell is p0e−cnC where cn is the rate of exponential
decay due to negative pressure.
In (8), sT denotes the constant supply rate of T cells
into the system from stem cells. The second term
is the natural death rate of T cells. The third term
is the rate at which T cells engage leukemia cells
and commit to n rounds of division. The final term
represents the population increase due to n divisions
of stimulated T cells where τ is the average duration
of one division, and Cnτ and Tnτ are the time delayed
cancer and T cell concentrations respectively. The
coefficient qT is the probability that a T cell survives
the encounter with an activated leukemia cell. The
method of modeling T cell proliferation in (8) is the
same as that used in DeConde et al [2005]. Once a T
cell is stimulated, it exits the collection of interacting
T cells and reenters the system nτ time units later after
n divisions. This approach ensures that the doubling
period of T cells saturates at nτ without a Michaelis-
Menten expression or other saturating terms.
Chen et al [2007] kept the parameter estimates from
Michor et al [2005] where applicable, and estimated
the remaining parameters based on patient data. We
estimated n, dT, sT, and cn for each patient separately.
The universal estimates that apply to all patients are
shown in Table A.3, and the particular parameters for
the three patients, labeled P1, P4,and P12, are shown
in Table A.4 in the Appendix.
Stability of fixed points. To solve for fixed points
(y¯0, y¯1, y¯2, y¯3, T¯ ), where C¯ = y¯0+y¯1+y¯2+y¯3, we set
all the derivatives in (4) and (8) to zero. After a series
of algebraic manipulations, we obtain the expression
e−κ1y¯0(κ2 + κ3y¯0)− κ4 = 0 (9)
where κ1 = cnγ, κ2 = sT/dT, κ3 = (2n − 1)(ry −
d0)/(dTqC), κ4 = (ry − d0)/(qCp0k), and γ =
ay
ry + d1 − d0
(
1 +
by
ry + d2 − d0
(
1 +
cy
ry + d3 − d0
))
.
Substituting the parameter values from Tables A.3
and A.4 and solving the implicit equation (9) numeri-
cally, we obtain values for y¯0. From y¯0, we can obtain
the other components, y¯1, y¯2, y¯3, T¯ . We find that every
patient has two fixed points (see Table A.1). These
fixed points correspond to equilibrium states where the
T cell response controls the leukemia population. For
every patient, fixed point 1 represents a much more
highly controlled state where leukemia is kept below
the cytogenetic remission level of about 0.01k/µL.
Thus, for medical purposes, fixed point 1 is a much
more desirable ending place for the dynamical sys-
tem. Next, for any fixed point (y¯0, y¯1, y¯2, y¯3, T¯ ), with
C¯ = y¯0 + y¯1 + y¯2 + y¯3, the linearization of (4) to (8)
can be written as x˙(t) = Ax(t)+bcTx(t−nτ) where
x = (y0, y1, y2, y3, T )T and
A11 = ry − d0 − qCp¯+ q¯1y¯0, A21 = ay + q¯1y¯1,
A12 = q¯1y¯0, A22 = −d1 − qCp¯+ q¯1y¯1,
A13 = q¯1y¯0, A23 = q¯1y¯1,
A14 = q¯1y¯0, A24 = q¯1y¯1,
A15 = −q¯2y¯0, A25 = −q¯2y¯1,
A31 = q¯1y¯2, A41 = q¯1y¯3,
A32 = by + q¯1y¯2, A42 = q¯1y¯3,
A33 = −d2 − qCp¯+ q¯1y¯2, A43 = cy + q¯1y¯3,
A34 = q¯1y¯2, A44 = −d3 − qCp¯+ q¯1y¯3,
A35 = −q¯2y¯2, A45 = −q¯2y¯3,
A51 = −p¯(1− cnC¯),
A52 = −p¯(1− cnC¯),
A53 = −p¯(1− cnC¯),
A54 = −p¯(1− cnC¯),
A55 = −dT − p¯1,
bT = (0 0 0 0 1) and cT = 2nqT·
·(p¯(1−cnC¯) p¯(1−cnC¯) p¯(1−cnC¯) p¯(1−cnC¯) p¯1).
Next, p(λ, τ) := p0(λ) + p1(λ)e−nτλ, where
p0(λ) = p00 + p01λ+ p02λ2 + p03λ3p04λ4 + p05λ5,
p1(λ) = p10 + p11λ+ p12λ2 + p13λ3p14λ4
and n is given in Table A.4 for each patient (see
Table A.5 for the corresponding coefficients). Let
f(ω) = 1−|a(jω)|, where a(jω) = −p1(jω)/p0(jω)
as in Proposition 1. If f(ω) = 0 has a root ω, then
|a(jω)| = 1. For a given ω0, the value of the analytic
function q(jω0, nτ), given in (2), equals zero when
τ =
arg(a(jω0))
ω0n
. (10)
Take arg(a(jω0)) ∈ [0, 2pi) to find the smallest posi-
tive τ . By (3) from Proposition 1, the crossing direc-
tion as τ increases is given by the sign of
<
[
a(jω0)
jω0cT b
]
. (11)
If (2) is satisfied, then a(jω0) = ejω0nτ . Furthermore,
ω0 > 0 and cT b = p¯1 > 0, so the sign of (11) is
the same as the sign of sin(ω0nτ). In our case, all
crossings are from the left to the right (i.e. toward
instability) as τ increases.
For all three patients, fixed point 1 gives one posi-
tive solution ω0, so there is one family of stability
crossings given by (10). On the other hand, for fixed
point 2, we always have |a(jω)| < 1, so there are no
stability crossings as τ increases. Also, for τ = 0,
fixed point 1 is stable for all three patients, while fixed
point 2 is unstable. This information is summarized
in Table A.2. Note that, for fixed point 1, the first
three eigenvalues are almost identical across the three
patients. From our numerical computations the eigen-
values match up to the first five significant digits, but
begin to vary after the sixth digit. Nonetheless, this
phenomenon is surprising, especially since the coef-
ficients of the quasipolynomial p(λ, τ) are different
across the three patients. (See Table A.5. Hence, it
appears that the first three eigenvalues of the charac-
teristic polynomial, obtained when τ =, are highly
insensitive to perturbations in the parameters sT, dT,
and cn. We are not sure why this is the case, so we
leave this problem for a future study. For all patients
P1, P4, and P12, fixed point 1 is stable for a wide range
of τ values. Biologically τ represents the duration in
days of one round of T cell division and is estimated to
be around one day Janeway et al [2005], Lee [2006],
Luzyanina et al [2004]. Hence, from a biological point
of view, the upper limit τc for stablity is unattainable,
and hence, the stability of fixed point 1 is independent
of any reasonable error in the estimation of the delay
τ . However, note that the real part of rightmost eigen-
values for fixed point 1 are of the order negative 10−3
to 10−4. Hence, the solution converges to the fixed
point very slowly. As τ increases from 0 to τc and
greater, the rightmost roots of p travel from C− across
jR and into C+. Figure A.1 shows the trajectories of
the rightmost characteristic roots for fixed points 1 of
P1, P4, and P12.
4. INTERPRETATIONS AND CONCLUSIONS
We find that in each of the three cases, P1, P4, and
P12, fixed point 1 is robustly stable for a wide range
of delays τ . The total leukemia concentrations for all
fixed points 1 fall well below the level of cytogenetic
remission. More accurately, the total leukemia con-
centrations fall at around 10−3k/µL, which is between
cytogenetic (10−2) and molecular (10−4) remission.
This robust stability implies that, as long as conditions
remain similar over time, the immune response is able
to control the leukemia population and gradually drive
it to a sustained cytogenetic remission. On the other
hand, the rate of convergence to this fixed point is
very slow, with an exponential convergence rate on
the order of at most 10−3/day. From a medical per-
spective, this rate of convergence is inadequate. In
addition, biological conditions are likely to change
over the extended time frame necessary for conver-
gence. Therefore, one method to improve the effec-
tiveness of Gleevec therapy is to induce the dynami-
cal system to settle down at the stable fixed point as
quickly as possible. This may be done by continually
measuring a patient’s leukemia load and modulating
the Gleevec dosage accordingly to ensure a stabilized
cancer population without high amplitude oscillations.
Such a method would involve formulating a delayed-
feedback control mechanism, in which the effects of
altering Gleevec dosages would become apparent only
after a time delay. This delay would have to be ac-
counted for when formulating a control strategy.
As a future work, we plan to develop a possible
delayed-feedback control mechanism to optimize the
effectiveness of Gleevec treatment on chronic myel-
ogenous leukemia. Furthermore, we intend to extend
the analysis to include the dependence of asymptotic
stability on the average number n of T cell divisions
after stimulation. Eventually, we plan to conduct a
more extensive sensitivity analysis to determine the
sensitivity of the model to key parameters.
REFERENCES
Angstreich, G. R., Smith, B. D., Jones, R. J.: Treat-
ment options for chronic myeloid leukemia: ima-
tinib versus interferon versus allogeneic transplant.
Curr. Opin. Oncol. 16 (2004) 95-99.
Antia, R., Bergstrom, C.T., Pilyugin, S.S., Kaech,
S.M., Ahmed, R.: Models of CD8+ responses: 1.
What is the antigen-independent proliferation pro-
gram. J Theor Biol. 221 (2003) 585-598.
Chen, C. I-U., Kim, P.S., Maecker, H.T., Levy, D.,
Lee, P.P.: Dynamics and Impact of the immune re-
sponse to chronic myelogenous leukemia. Submit-
ted for publication.
Cortes, J. et al.: Molecular responses in patients with
chronic myelogenous leukemia in chronic phase
treated with imatinib mesylate. Clin. Cancer Res.11
(2005) 3425-3432
De Boer, R.J., Homann, D., Perelson, A.S.: Different
dynamics of CD4+ and CD8+ T cell responses dur-
ing and after acute lymphocytic choriomeningitis
virus infection. J Immunol. 171 (2003) 3928-3935.
DeConde, R., Kim, P.S., Levy, D., Lee, P.P.: Post-
transplantation dynamics of the immune response to
chronic myelogenous leukemia. J Theor Biol. 236
(2005) 39-59.
Gannage, M. et al.: Ex vivo characterization of multi-
epitopic tumor-specific CD8 T cells in patients with
chronic myeloid leukemia: implications for vaccine
development and adoptive cellular immunotherapy.
J. Immunol. 174 (2005) 8210-8218.
Janeway, C.A. Jr., Travers, P., Walport, M., Shlom-
chik, M.J.: Immunobiology : the immune system in
health and disease 6th ed. (Garland Science Pub-
lishing: New York, NY 2005.)
Kuang, Y.: Delay differential equations with appli-
cations in population dynamics (Academic Press,
Boston, 1993).
Lee, P.P.: Unpublished data, 2006.
Lee, S. J.: Chronic myelogenous leukaemia. Br. J.
Haematol. 111 (2000) 993-1009.
Luzyanina, T., Engelborghs, K., Ehl, S., Klenerman,
P., Bocharov, G.: Low level viral persistence after
infection with LCMV: a quantitative insight through
numerical bifurcation analysis. Math. Biosci. 173
(2004) 1-23.
Michor, F., Hughes, T.P., Iwasa, Y., Branford, S.,
Shah, N.P., Sawyers, C.L., Nowak, M.A.: Dynamics
of chronic myeloid leukaemia. Nature 435 (2005)
1267-1270.
Mohty, M. et al.: Imatinib and plasmacytoid den-
dritic cell function in patients with chronic myeloid
leukemia. Blood 103 (2004) 4666-4668.
Moore, H., Li, N.K.: A mathematical model for
chronic myelogenous leukemia (CML) and T cell
interaction. J. Theor. Biol. 227 (2004) 513-523.
Murray, J.D.: Mathematical Biology (BioMath. 18,
Springer: Berlin, 2nd Edition, 1993).
Niculescu, S.-I., Kim, P.S., Lee, P.P. and Levy, D.
(2007). On stability of a combined Gleevec and im-
mune model in chronic leukemia: Exploiting delay
system structure. (full version of the paper).
Neiman, B.: A Mathematical Model of Chronic Myel-
ogenous Leukemia. M.Sc. Dissertation (2002), Uni-
versity College, Oxford University, UK.
Sato, N. et al.: The effects of STI571 on antigen pre-
sentation of dendritic cells generated from patients
with chronic myelogenous leukemia. Hematol. On-
col. 21 (2003) 67-75.
Appendix A. APPENDIX: PARAMETER TABLES, COEFFICIENTS AND FIGURES
Patient P1 P4 P12
Fixed pt. 1 2 1 2 1 2
y¯0 1.3312 e-5 1.5978 e-1 1.2844 e-5 1.7953 e-2 6.6409 e-5 1.5597 e-1
y¯1 1.8127 e-5 2.1757 e-1 1.7490 e-5 2.4447 e-2 9.0429 e-5 2.1238 e-1
y¯2 5.5883 e-6 6.7074 e-2 5.3918 e-6 7.5365 e-3 2.7878 e-5 6.5475 e-2
y¯3 7.3943 e-4 8.8752 7.1344 e-4 9.9723 e-1 3.6888 e-3 8.6636
T¯ 9.5908 e-3 9.1113 e+1 9.6332 e-3 1.2894 e+1 9.6126 e-3 1.2247 e+1
Table A.1. Fixed points for patients P1, P4, and P12.
Patient P1 P4 P12
Fixed point 1
ωc 6.4626 e-4 1.7701 e-3 7.9424 e-4
τc 185.75 86.672 291.02
-7.5575 e-1 -7.5575 e-1 -7.5575 e-1
Eigenvalues/ -4.3250 e-2 -4.3250 e-2 -4.3250 e-2
roots of p(λ, τ) -1.1750 e-2 -1.1750 e-2 -1.1750 e-2
for τ = 0 -4.5164 e-4 + 5.6771 e-4 j -6.9802 e-4 + 1.9732 e-3 j -6.2610 e-3
-4.5164 e-4 - 5.6771 e-4 j -6.9802 e-4 - 1.9732 e-3 j -3.3455 e-4
Fixed point 2
ωc None None None
τc None None None
-7.5490 e-1 -7.5507 e-1 -7.5507 e-1
Eigenvalues/ -4.2401 e-2 -4.2571 e-2 -4.2575 e-2
roots of p(λ, τ) -1.0901 e-2 -1.1071 e-2 -1.1075 e-2
for τ = 0 -9.8591 e-4 -2.0606 e-3 -6.8221 e-3
4.6607 e-2 3.8423 e-2 3.8059 e-2
Table A.2. Roots ωc and delays τc correspond to the first stability crossing. In each case,
for fixed point 1, there is one family of stability crossings, and the eigenvalues for τ = 0
have only negative real parts. Hence, fixed point 1 is stable for τ ∈ [0, τc). In each case,
for fixed point 2, there is no stability crossing and eigenvalues for τ = 0 has one root with
positive real part. Hence, fixed point 2 is unstable for all non-negative τ .
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Fig. A.1. Trajectories of rightmost eigenvalues of fixed points 1 as τ increases. Conjugate eigenvalues (not shown)
follow analogous paths in the lower half of the complex plane.
Param Description Estimate Ref./Reasoning
λd0 SC death rate 0.003λ/day Michor et al [2005]
λd1 PC death rate 0.008λ
λd2 DC rate 0.05λ
λd3 TC death rate λ
ry Growth rate for nonresistant cells 0.008/day Michor et al [2005]
ay Rates without Gleevec treatment 1.6
by 10
cy 100
a′y Rates during Gleevec treatment ay/100 Michor et al [2005]
b′y by/750
c′y cy
k Kinetic coefficient 1(k/µL)−1day−1 DeConde et al [2005], Luzyanina et al [2004]
p0 Prob. T cell engages cancer cell 0.8 Lee [2006]
qC Prob. cancer cell dies from encounter 0.75
qT Prob. T cell survives encounter 0.5
τ Duration of one division 1 day Janeway et al [2005], Lee [2006], Luzyanina et al [2004]
y0(0) Initial conc. Determined by patient data
y1(0) Initial concentration ayy0/d1 Steady state
y2(0) Initial concentration byy1/d2 Steady state
y3(0) Initial concentration cyy2/d3 Steady state
z0(0) Initial concentration 0 or 10−9 Correspond to values in Michor et al [2005]
z1(0) Initial concentration azz0/d1 Steady state
z2(0) Initial concentration bzz1/d2 Steady state
z3(0) Initial concentration czz2/d3 Steady state
T (0) Initial concentration sT/dT Steady state
Table A.3. Universal parameter estimates for all patients.
Param Description (units) Estimates (P1, P4, P12)
y0(0) Initial conc. of leukemia stem cells (k/µL) 7.6× 10−6 2.4× 10−6 1.2× 10−5
n Average # of T cell divisions 2.2 1.2 1.17
dT T cell death rate 0.001 0.0022 0.007
sT T cell supply rate 2× 10−6 9× 10−7 3.08× 10−5
cn Decay rate of immune responsitivity 1 7 0.8
Table A.4. Parameters for patients P1, P4, and P12.
Patient P1 P4 P12
Fixed pt. 1 2 1 2 1 2
p00 -1.3724 e-9 -1.7573 e-8 -1.3423 e-9 -3.0756 e-8 -6.8706 e-9 -1.0401 e-7
p01 4.7040 e-7 -1.7700 e-5 9.1513 e-7 -1.6032 e-5 3.1151 e-6 -2.1081 e-5
p02 4.4917 e-4 -1.5173 e-3 4.9758 e-4 -1.1523 e-3 7.9328 e-4 -9.2864 e-4
p03 4.3381 e-2 4.3982 e-3 4.4313 e-2 1.2502 e-2 5.0221 e-2 2.0000 e-2
p04 8.1237 e-1 7.6335 e-1 8.1351 e-1 7.7361 e-1 8.2082 e-1 7.8314 e-1
p05 1 1 1 1 1 1
p10 1.5745 e-9 1.5403 e-9 3.0247 e-9 2.5814 e-9 7.6750 e-9 1.1576 e-8
p11 -1.0134 e-7 -8.8209 e-8 -1.9467 e-7 -1.5171 e-7 -4.9396 e-7 -6.8072 e-7
p12 -2.6675 e-5 -2.7680 e-5 -5.1243 e-5 -4.5825 e-5 -1.3003 e-4 -2.0544 e-4
p13 -5.7395 e-4 -6.1609 e-4 -1.1026 e-3 -1.0130 e-3 -2.7978 e-3 -4.5407 e-3
p14 -7.1298 e-4 -7.6776 e-4 -1.3697 e-3 -1.2615 e-3 -3.4755 e-3 -5.6548 e-3
Table A.5. Coefficients of the quasipolynomials for patients P1, P4, and P12.
